Glomerular disease: Targeted steroid therapy for IgA nephropathy
Nature Reviews Nephrology 13, 390 (2017).
doi:10.1038/nrneph.2017.65
Author: Richard J. Glassock
Encouraging preliminary data from the NEFIGAN trial suggest that a novel oral formulation of budesonide might reduce disease progression in IgA nephropathy. This formulation releases corticosteroid in the distal small intestine and colon, so is thought to directly target the mucosal element of the pathogenesis of the disease.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Richard J. Glassock Tags: News and Views Source Type: research